联合检测ERCC1和生存素在非小细胞肺癌个体化治疗中的意义  

Significance of combined detection of ERCC1 and survivin in guiding individuallized therapy for nonsmall cell lung cancer

作　　者：朱建荣[1] 惠复新[1] 卞涛[1] 

机构地区：[1]南京医科大学附属无锡市人民医院呼吸病科,江苏省214023

出　　处：《江苏医药》2015年第4期433-436,共4页Jiangsu Medical Journal

摘　　要：目的探讨联合检测肿瘤组织中核苷酸切除修复交叉互补基因1(ERCC1)和生存素蛋白的表达指导非小细胞肺癌(NSCLC)个体化治疗的价值。方法确诊为NSCLC患者151例,随机进入个体化治疗(A组,101例)和标准治疗(B组,50例)两组。A组依据活检组织标本中ERCC1及生存素蛋白表达情况选择个体化方案化疗:两种蛋白表达均为阴性的患者采用含铂一线化疗方案;其他患者则选用非铂化疗方案。B组均选择含铂一线化疗方案。比较两组患者化疗有效率和总生存期。结果 A组化疗有效率高于B组(49.5%vs.32.0%)(P<0.05);A组中位生存时间比B组长(13.81个月vs.11.50个月)(P<0.05)。结论联合检测肿瘤组织中ERCC1和生存素蛋白指导NSCLC患者个体化治疗可以提高化疗效果,延长生存时间。Objective To investigate clinical significance of combined detection of excisionrepair-cross-complement-1（ERCC1）and survivin in cancer biopsy samples in guiding individualized therapy for non-small cell lung cancer（NSCLC）.Methods A total of 151 patients with NSCLC diagnosed pathologically was randomly assigned into two groups of A（treated with individualized scheme,101cases）and B（treated with standard first-line platinum-based chemotherapy,50cases）.On th basis of ERCC1 and survivin detection in cancer biopsy samples,the standard first-line platinumbased chemotherapy was performed in the cases with negative ERCC1 and survivin and the others were treated with nonplatinum-based chemotherapy in group A.The effectiveness and survival rates were compared.Results The overall effectiveness rate was higher in group A than that in group B（49.5% vs.32.0%）（P〈0.05）.The overall median survival time was lomger in group A than that in group B（13.81 months vs.11.50 months）（P〈0.05）.Conclusion Guided by combined detection of ERCC1 and survivin proteins in biopsy samples,the individualized chemotherapy may improve therapeutic effectiveness rate and prolong survival time in the patients with NSCLC.

关 键 词：非小细胞肺癌 核苷酸切除修复交叉互补基因1 生存素 

分 类 号：R734[医药卫生—肿瘤]